Adicet's $100.9m cash to last into 2H 2027 as lupus pivotal prep proceeds
The cell-therapy developer reported third-quarter results alongside a prostate cancer IND clearance and Fast Track status, and an upcoming FDA meeting on widening its lupus plans.
Adicet Bio ended the third quarter with $100.9 million in cash, which the company says is enough to fund operations into the second half of 2027. That runway has to cover two programmes moving into more demanding stages: a pivotal study in lupus nephritis and a newly cleared prostate cancer candidate. The company reported the figures on 5 November.
In oncology, the US Food and Drug Administration cleared the investigational new drug application for ADI-212 in metastatic castration-resistant prostate cancer in August. The agency added Fast Track Designation in September. The status is meant for therapies aimed at serious conditions with unmet need, and it typically brings more frequent contact with the regulator. The company's update gave no timelines or pivotal plans for the prostate programme.
In autoimmune disease, Adicet said start-up work is under way for a pivotal study of prula-cel in lupus nephritis. It described Phase 1 lupus data as showing lasting responses, and reported no cytokine release syndrome, ICANS or graft-versus-host disease above Grade 2.
The next regulatory checkpoint is a meeting with the FDA planned for the fourth quarter of 2026. Adicet wants to discuss extending the pivotal programme to lupus patients without kidney involvement. The update did not say what the company expects from that discussion.
Why it matters
- Cash of $100.9m, guided to last into 2H 2027, sets the financial window for the lupus nephritis pivotal start-up and the early prostate work.
- The Q4 2026 FDA meeting on lupus without nephritis could affect how large the prula-cel pivotal programme becomes.
- Reported safety of no CRS, ICANS or GvHD above Grade 2 in lupus Phase 1 data is a point for teams tracking cell-therapy risk in autoimmune indications.
- Fast Track for ADI-212 allows closer FDA dialogue, but no prostate cancer timelines or pivotal details have been disclosed.
Company's press release (SEC filing): Adicet Bio, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
Valneva: 94% of adults still seroresponders five years after single IXCHIQ dose
GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage
